Nektar (NKTR) Director Robert Chess Receives RSU Award

What Happened

• Robert Chess, a director of Nektar Therapeutics (NKTR), was granted equity awards on September 23, 2026: 2,000 shares listed as acquired (RSUs) and 4,000 shares listed as a derivative award. Both awards show $0 purchase price (typical for RSU grants) and total reported acquisition value $0.
• The filing shows these are restricted stock units (RSUs); each RSU is a contingent right to receive one share of common stock upon vesting. One RSU award vests in full one year after September 23, 2026 (i.e., on/around 9/23/2027).

Key Details

• Transaction date: 2026-09-23; Form 4 filed: 2026-09-25 (filed within the usual 2-business-day window for Section 16 reporting).
• Reported grants: 2,000 RSUs (acquired) and 4,000 RSU-derivative (acquired), price reported $0.00; reported acquisition value $0.
• Shares owned after the transaction: Not specified in the filing.
• Notable footnotes in the filing:
  • F1: Awards are RSUs; each converts to one share upon vesting.
  • F2: One RSU award vests in full one year after 9/23/2026.
  • F3: All amounts adjusted for a 1-for-15 reverse stock split effective 6/8/2025.
  • F4: Reporting person disclaims beneficial ownership of these shares per the filing.
  • F5: The filing also contains a footnote saying a stock option vests in equal monthly installments over one year beginning 9/23/2026 (appears as additional award terms in the filing).

Context

• RSU grants are a compensation award (not an immediate purchase) and represent a future right to stock if vesting conditions are met; they are not an immediate liquidity event or sale.
• The derivative line simply reflects RSUs (contingent rights) rather than currently owned common shares; they convert to shares only upon vesting.
• Filing appears timely (reported two days after the transaction date), so no late-filing flag was indicated.